Genmab Yönetim
Yönetim kriter kontrolleri 2/4
Şu anda CEO hakkında yeterli bilgiye sahip değiliz.
Anahtar bilgiler
Jan G.J. de Winkel
İcra Kurulu Başkanı
US$10.7m
Toplam tazminat
| CEO maaş yüzdesi | 14.02% |
| CEO görev süresi | 16yrs |
| CEO sahipliği | 1.1% |
| Yönetim ortalama görev süresi | 6.3yrs |
| Yönetim Kurulu ortalama görev süresi | 8.3yrs |
Son yönetim güncellemeleri
Recent updates
Anlatı Güncellemesi • Jun 10
GMAB: 2026 Readouts And Commercial Pivot Will Shape Bullish Outlook
Genmab’s consensus analyst price target has been reset lower from DKK 2,233 to DKK 2,313, with analysts citing a more commercially focused platform, evolving assumptions for revenue growth and margins, and updated P/E expectations following recent research on key pipeline readouts and price target revisions. Analyst Commentary Recent research on Genmab reflects a mix of optimism around the product pipeline and caution around valuation assumptions and execution risks.
Anlatı Güncellemesi • May 26
GMAB: Late Stage Oncology Readouts Will Support Stronger Margins And Earnings Quality
Genmab's analyst price target has been trimmed slightly to DKK 3,000, as analysts factor in more measured revenue growth expectations, a modestly higher discount rate, and a somewhat richer forward P/E outlook. They are still pointing to solid margin potential and recent bullish rating updates from several firms.Analiz Makalesi • May 15
There May Be Some Bright Spots In Genmab's (CPH:GMAB) Earnings
The most recent earnings report from Genmab A/S ( CPH:GMAB ) was disappointing for shareholders. While the headline...Analiz Makalesi • May 11
Analyst Estimates: Here's What Brokers Think Of Genmab A/S (CPH:GMAB) After Its First-Quarter Report
Genmab A/S ( CPH:GMAB ) shareholders are probably feeling a little disappointed, since its shares fell 3.9% to kr.1,642...
Anlatı Güncellemesi • Apr 29
GMAB: 2026 Pipeline Catalysts Will Test Balanced Risk And Opportunity Outlook
Narrative Update on Genmab The updated analyst framework lifts Genmab's fair value estimate from DKK 1,300 to about DKK 1,588. This reflects higher assumed revenue growth and P/E multiples as analysts factor in recent upgrades, resumed coverage and new acquisition driven pipeline contributions.Anlatı Güncellemesi • Apr 15
GMAB: 2026 Clinical Readouts And AI Use Will Shape Outlook
Genmab's updated analyst price target edges slightly lower to DKK 2,233 from DKK 2,238, as analysts factor in mixed views around Epkinly assumptions, acquisition driven pipeline updates, and a modestly higher future P/E expectation despite broadly constructive long term growth potential. Analyst Commentary Recent research on Genmab reflects a mix of optimism around the expanded pipeline and upcoming catalysts, alongside caution tied to Epkinly assumptions and valuation.Anlatı Güncellemesi • Mar 31
GMAB: 2026 Late Stage Oncology Catalysts Will Support Stronger Margin Profile
Genmab's updated analyst price target now sits at DKK 3,017, a modest reset from DKK 3,060 as analysts factor in higher discount rates, revised long term margin expectations, and recent research that reflects both increased revenue growth assumptions and a lower future P/E multiple. Analyst Commentary Recent Street research around Genmab has centered on how new clinical and portfolio developments filter into valuation, with several bullish analysts updating price targets and investment cases to reflect revised expectations on execution and long term growth potential.Anlatı Güncellemesi • Mar 17
GMAB: 2026 Catalyst Calendar Will Likely Expose Downside Risk Ahead
Analysts have lifted the Genmab fair value estimate from DKK 1,075.93 to DKK 1,300.00, reflecting updated views on revenue growth, profitability and future P/E, following recent price target revisions and renewed coverage across the Street. Analyst Commentary Recent Street research on Genmab points to a mix of optimism and caution, with valuation views reset around updated expectations for key pipeline assets and royalty streams.Anlatı Güncellemesi • Mar 03
GMAB: 2026 Catalyst Events And AI Adoption Will Shape Outlook
Genmab's analyst fair value estimate has moved up from DKK 2,182 to DKK 2,238, as analysts factor in higher long term revenue growth assumptions, a higher future P/E and recent price target revisions around DKK 2,400 to DKK 2,500, even as they temper near term expectations for Epkinly and margins. Analyst Commentary Recent research points to a more nuanced view of Genmab, with several firms adjusting their price targets and models following the latest earnings, product updates and acquisition activity.Anlatı Güncellemesi • Feb 17
GMAB: 2026 Pipeline Readouts And AI Use Will Drive Outlook
Analysts have made a small trim to their blended DKK price target on Genmab, with the model now pointing to roughly DKK 2,182. This reflects updated assumptions around slightly higher discount rates, a modestly different margin outlook and a lower future P/E multiple after recent coverage resets and target hikes from banks like Morgan Stanley, Deutsche Bank and Barclays.Anlatı Güncellemesi • Feb 02
GMAB: Phase 3 Data, AI Adoption And 2026 Readout Will Shape Outlook
Genmab’s analyst fair value estimate has moved modestly higher to DKK 2,188.94. Analysts point to updated assumptions around slightly lower discount rates, adjusted revenue growth and profit margin expectations, and a recalibrated future P/E multiple as the key drivers behind the refreshed price targets.Anlatı Güncellemesi • Jan 19
GMAB: Phase 3 Setback And 2026 Readout Will Shape Market Outlook
Genmab’s analyst price target has been lifted by roughly DKK 100 to reflect updated expectations around slightly higher revenue growth and profit margin assumptions, as analysts point to recent target increases from DKK 2,000 to DKK 2,400 and DKK 2,500 as support for a higher fair value range. Analyst Commentary Recent Street research on Genmab reflects a generally constructive stance, with higher price targets and continued attention on upcoming clinical milestones.Anlatı Güncellemesi • Jan 05
GMAB: Late Stage Oncology Focus Will Drive Stronger Margins And Repricing
Analysts have increased their fair value estimate for Genmab from DKK 2,700 to approximately DKK 3,060, reflecting updated assumptions that combine lower projected revenue growth with higher profit margins and a reduced future P/E multiple. What's in the News Genmab plans to discontinue further clinical development of acasunlimab and to concentrate resources on late stage programs such as EPKINLY (epcoritamab), petosemtamab and rinatabart sesutecan, described as part of its disciplined portfolio and capital allocation framework (Key Developments).Anlatı Güncellemesi • Dec 14
GMAB Merus Deal Will Likely Expose Downside Risk At Current Levels
Analysts have lifted Genmab's fair value estimate from DKK 1,015 to about DKK 1,076, reflecting a series of higher price targets that cite the Merus acquisition's boost to the late stage pipeline and underappreciated royalty revenue upside as key drivers. Analyst Commentary Recent Street research on Genmab remains broadly constructive, with multiple firms lifting price targets and highlighting the strategic merits of the Merus acquisition.Anlatı Güncellemesi • Nov 29
GMAB: Merus Acquisition and Pipeline Depth Will Shape Market Outlook
Genmab's analyst price target has seen a modest decrease of approximately DKK 3.57 to DKK 2,054.66. Analysts are factoring in sustaining growth drivers from recent pipeline acquisitions while adjusting for updates to discount rate and margin assumptions.Anlatı Güncellemesi • Nov 15
GMAB: Future Pipeline Expansion and Merus Acquisition Will Define Performance
Genmab's analyst price target has been raised from approximately DKK 2,017 to DKK 2,058. This reflects analysts' increased confidence in the company's pipeline expansion, notably following the Merus acquisition and upside potential from key assets such as Epkinly.Anlatı Güncellemesi • Nov 01
GMAB: Recent Acquisition Will Drive Pipeline Expansion While Integration Risks Remain
Genmab's fair value estimate has been raised from DKK 2,012.92 to DKK 2,017.35. Analysts highlight the Merus acquisition's positive impact on the late-stage pipeline and renewed confidence in royalty revenue growth opportunities.Anlatı Güncellemesi • Oct 18
Pipeline Progress And International Expansion Will Unlock Market Opportunities
Genmab's analyst fair value target has increased slightly, rising from DKK 2,005 to DKK 2,013. Analysts cite royalty revenue upside and pipeline expansion following recent M&A activity as key drivers for the upward revisions.Anlatı Güncellemesi • Oct 04
Pipeline Progress And International Expansion Will Unlock Market Opportunities
Genmab's analyst price target was raised from approximately $1,942 to $2,005. This reflects increased confidence among analysts in the company's growth outlook and pipeline expansion following recent acquisitions.Analiz Makalesi • Sep 24
Here's Why We Think Genmab (CPH:GMAB) Might Deserve Your Attention Today
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...Anlatı Güncellemesi • Sep 04
Pipeline Progress And International Expansion Will Unlock Market Opportunities
Genmab’s consensus price target was unchanged at DKK1942, as strong sales momentum and positive pipeline updates were offset by concerns about rising competition and tempered long-term growth expectations. Analyst Commentary Bullish analysts are raising price targets following stronger-than-expected sales momentum for Genmab's key oncology products.Analiz Makalesi • Jul 31
Investors Aren't Entirely Convinced By Genmab A/S' (CPH:GMAB) Earnings
When close to half the companies in Denmark have price-to-earnings ratios (or "P/E's") above 16x, you may consider...
Yeni Anlatı • Nov 11
Decisive Advances And DuoBody Innovation Propel Future Growth In Biotech Frontiers
Genmab's focus on late-stage therapies, particularly EPKINLY, is expected to boost future revenue and growth due to best-in-class technology and market approvals.CEO Tazminat Analizi
| Tarih | Toplam Tazminat | Maaş | Şirket Kazançları |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | US$821m |
| Dec 31 2025 | US$11m | US$2m | US$963m |
| Sep 30 2025 | n/a | n/a | US$2b |
| Jun 30 2025 | n/a | n/a | US$1b |
| Mar 31 2025 | n/a | n/a | US$1b |
| Dec 31 2024 | US$8m | US$1m | US$1b |
| Sep 30 2024 | n/a | n/a | US$702m |
| Jun 30 2024 | n/a | n/a | US$798m |
| Mar 31 2024 | n/a | n/a | US$791m |
| Jan 01 2024 | n/a | n/a | US$631m |
| Sep 30 2023 | n/a | n/a | US$590m |
| Jun 30 2023 | n/a | n/a | US$680m |
| Mar 31 2023 | n/a | n/a | US$757m |
| Dec 31 2022 | US$6m | US$1m | US$785m |
| Sep 30 2022 | n/a | n/a | US$745m |
| Jun 30 2022 | n/a | n/a | US$558m |
| Mar 31 2022 | n/a | n/a | US$354m |
| Dec 31 2021 | US$6m | US$1m | US$452m |
| Sep 30 2021 | n/a | n/a | US$448m |
| Jun 30 2021 | n/a | n/a | US$401m |
| Mar 31 2021 | n/a | n/a | US$880m |
| Dec 31 2020 | US$6m | US$1m | US$781m |
| Sep 30 2020 | n/a | n/a | US$889m |
| Jun 30 2020 | n/a | n/a | US$853m |
| Mar 31 2020 | n/a | n/a | US$349m |
| Dec 31 2019 | US$5m | US$1m | US$325m |
Tazminat ve Piyasa: Jan G.J. 'nin toplam tazminatı ($USD 10.70M ), Danish pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 4.02M ).
Tazminat ve Kazançlar: Jan G.J. şirketinin tazminatı %20'den fazla artarken, şirketin kazancı geçen yıl %20'den fazla düştü.
CEO
Jan G.J. de Winkel (65 yo)
16yrs
Görev süresi
US$10,700,000
Tazminat
Dr. Jan G.J. van de Winkel, Ph.D. was Independent Director of HOOKIPA Pharma Inc. from 2023 until August 30, 2024 and served as Chairman of the Board since 2024 August 30, 2024. Dr. Winkel served as a Memb...
Liderlik Ekibi
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| Co-Founder | 16yrs | US$10.70m | 1.07% DKK 1.1b | |
| Executive VP & CFO | 6.3yrs | US$4.70m | 0.017% DKK 16.8m | |
| Executive VP & Chief Technical Operations Officer | 1.8yrs | US$2.70m | Veri yok | |
| Executive VP | less than a year | US$1.80m | Veri yok | |
| Executive VP & Chief People Officer | 8.6yrs | US$3.40m | Veri yok | |
| Executive VP & Chief Strategy Officer | 12.4yrs | US$2.40m | Veri yok | |
| Senior Director | no data | US$300.00k | 0.0014% DKK 1.4m | |
| Executive VP & Chief Development Officer | 9.3yrs | US$5.40m | 0.025% DKK 25.3m | |
| Executive VP | 5.3yrs | US$5.20m | 0.016% DKK 16.4m | |
| VP, Head of Antibody Research Materials & Director | no data | US$300.00k | 0.0014% DKK 1.4m | |
| Senior Director of Finance Japan & Non-Independent Director | no data | US$100.00k | 0.00013% DKK 129.9k | |
| Executive VP & Chief Commercial Officer | 1.8yrs | US$2.10m | Veri yok |
6.3yrs
Ortalama Görev Süresi
54yo
Ortalama Yaş
Deneyimli Yönetim: GMAB 'un yönetim ekibi deneyimli ve deneyimlidir ( 6.3 yıldır).
Yönetim Kurulu Üyeleri
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| Senior Director | 4.4yrs | US$300.00k | 0.0014% DKK 1.4m | |
| VP, Head of Antibody Research Materials & Director | 7.3yrs | US$300.00k | 0.0014% DKK 1.4m | |
| Senior Director of Finance Japan & Non-Independent Director | 4.4yrs | US$100.00k | 0.00013% DKK 129.9k | |
| Senior Director | 1.4yrs | US$200.00k | 0% DKK 0 | |
| Non-Independent Director | 22.6yrs | US$400.00k | 0.013% DKK 12.5m | |
| Independent Director | 4.3yrs | US$400.00k | 0.0031% DKK 3.1m | |
| Independent Chairman of the Board | 9.3yrs | US$600.00k | 0.011% DKK 10.7m | |
| Independent Director | 9.3yrs | US$400.00k | 0.0062% DKK 6.2m | |
| Independent Deputy Chairman | 11.4yrs | US$400.00k | 0.0089% DKK 8.9m | |
| Independent Director | 11.4yrs | US$300.00k | 0.0041% DKK 4.1m |
8.3yrs
Ortalama Görev Süresi
60.5yo
Ortalama Yaş
Deneyimli Yönetim Kurulu: GMAB 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 8.3 yıldır).
Şirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/06/19 01:14 |
| Gün Sonu Hisse Fiyatı | 2026/06/19 00:00 |
| Kazançlar | 2026/03/31 |
| Yıllık Kazançlar | 2025/12/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları GitHub sayfamızda mevcuttur; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube'da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
Genmab A/S 39 Bu analistlerden 22, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| James Gordon | Barclays |
| Xue Chen | Barclays |
| Emily Field | Barclays |